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Abstract 
The human papillomavirus (HPV) vaccine is the most effective way to prevent HPV-related cancers. Integrating 
provider vaccine counseling is crucial to improving HPV vaccine completion rates. Automating the counseling 
experience through a conversational agent could help improve HPV vaccine coverage and reduce the burden of 
vaccine counseling for providers. In a previous study, we tested a simulated conversational agent that provided HPV 
vaccine counseling for parents using the Wizard of OZ protocol. In the current study, we assessed the conversational 
agent among young college adults (n=24), a population that may have missed the HPV vaccine during their 
adolescence when vaccination is recommended. We also administered surveys for system and voice usability, and for 
health beliefs concerning the HPV vaccine. Participants perceived the agent to have high usability that is slightly 
better or equivalent to other voice interactive interfaces, and there is some evidence that the agent impacted their 
beliefs concerning the harms, uncertainty, and risk denials for the HPV vaccine. Overall, this study demonstrates the 
potential for conversational agents to be an impactful tool for health promotion endeavors. 
Introduction 
High-risk types of human papillomavirus (HPV) can lead to serious cancers in adults – including cervical, penile, head 
and neck, and several others. The most effective method to protect against HPV-related cancers is the HPV vaccine, 
which has been proven to protect against exposure to this virus1. Unfortunately, HPV vaccination rates continue to be 
lower than the targeted goal of 80%2. One predictive study mentioned that if at least 70% of the population were to 
receive the HPV vaccine, up to 6 million deaths could be prevented. One key tactic to increase the rate of HPV 
vaccination is patient-provider communication3, 4. In several studies, patient-provider communication has resulted in 
an effect on HPV vaccine uptake, as many patients and consumers prefer to discuss the HPV vaccine with their 
provider to make a decision5-10. Furthermore, patient-provider communication is a method endorsed by the President’s 
Cancer Council to improve HPV vaccination rates11.  
The practice of patient-centered care has risen to prominence in recent years. Traditional medical care is physician-
centered, in which physicians are seen to hold positions of authority over patients, but under the patient-centered 
approach, the patient’s needs, feelings, concerns, and expectations are prioritized. This enables the physician to fully 
understand the patient’s perspective to provide the best care possible. Effective communication between providers 
and patients is critical to facilitate exchange of information necessary for diagnosis and treatment while establishing 
mutual trust, involving both instrumental and affective behaviors.  
Instrumental communication fulfills a patient’s “need to know and understand,” while affective communication fulfills 
a patient’s “need to feel known and understood”12. More specifically, instrumental communication involves asking 
the patient questions about their symptoms, informing them of a diagnosis and treatment options, and discussing 
possible side effects. Meanwhile, affective communication involves being open and honest, expressing empathy, and 
addressing the patient by name—above all, viewing the patient as a person, rather than just a medical case. Only 7% 
of affective communication is verbal; non-verbal cues include tone of voice, eye contact, facial expressions, body 
language, and physical proximity13. Patients are extremely sensitive to these cues and may question their physician’s 
 
 
  
genuineness if their verbal utterances seem inconsistent with their non-verbal behaviors (such as if the physician was 
withholding information about the severity and prognosis of the disease).  
There are many positive effects of providing patient-centered care through instrumental and affective communication. 
These outcomes include increased patient satisfaction and understanding, which depend greatly on non-verbal 
affective behavior of physicians such as physical proximity14. On the other hand, dominant and controlling behaviors, 
such as frequent interruption to overshadow the patient in conversation, result in decreased patient satisfaction15. A 
physician may underestimate their patient’s desire for information or fail to adequately communicate this information 
by using medical terms instead of everyday language, which may cause misunderstandings and lead to patient 
dissatisfaction and non-compliance. Additionally, patient-centered care is empowering; cancer patients who were 
given the opportunity to participate in decision-making about their treatment experienced higher quality of life and 
less anxiety16.   
Moreover, research has shown that the patient-centered approach produces optimal health outcomes, which is the 
ultimate aim of medical care. This may occur through direct or indirect pathways; for instance, clear communication 
would facilitate mutual understanding and trust, which could increase patient adherence and improve their condition17. 
Better-quality communication during history-taking and discussion of management plan is associated with symptom 
resolution, pain control, and physiological measures such as blood pressure and blood sugar level18. When patients 
perceive that their visit was patient-centered—especially if they found common ground with the physician for their 
management plan—they experienced better physical and emotional health19. Also, diagnostic tests and referrals two 
months after the visit were half as frequent if it was perceived to be patient-centered, which indicates increased 
efficiency of care.  
Another important perspective to consider is that the implementation of patient-centered care addresses racial, ethnic, 
and socioeconomic disparities and improves access to health care for disadvantaged populations. These patient 
populations tend to ask fewer questions during visits and have lower health literacy, which often leads to worse 
outcomes20-22; for this reason, it is especially important to prioritize their perspective and help them fully understand 
their condition and treatment23, 24. Patients who lack health insurance and a consistent health care provider, or who 
have negative perceptions of their general health, also tend to rate provider-patient communication more 
unfavorably25. As these patients are most in need of effective communication with their physicians, open discussion 
should be encouraged to engage with them and help them access health services and community resources17.  
Despite the benefits of patient-centered communication, most physicians do not receive adequate training to develop 
these communication skills, which tend to deteriorate over time26, 27. In fact, complaints about clinical care typically 
arise due to poor communication, rather than technical competency issues. Common reasons for malpractice claims 
in the United States involve inadequate explanation of diagnosis or treatment and patients feeling ignored, devalued, 
or rushed28. Meanwhile, physicians tend to overestimate their communication skills: for instance, in a national survey 
conducted by the American Academy of Orthopedic Surgeons, 75% of orthopedic surgeons reported satisfactory 
communication with patients, but only 21% of patients reported satisfactory communication with their surgeons29.  
One potential concern of patient-centered care is that physicians “responding to every whim of the patient” may 
increase expenses to the health care system19. However, physicians with a more patient-centered communication style 
actually have fewer standardized diagnostic testing expenditures, as well as total standardized expenditures30. While 
these physicians tend to have longer visits with patients, there was no relationship between visit length and costs after 
adjusting for patient-centered communication scores. Nevertheless, longer visits are associated with preventive 
services, such as vaccination28. When recommending vaccines to patients, applying patient-centered communication 
is especially important to fully address their perceptions and concerns about vaccination, thereby promoting a shared 
understanding between physicians and patients that is essential for highly individualized clinical discourse.   
The quality of a provider’s recommendations for the HPV vaccine may have an impact on parents’ decisions to 
vaccinate their children. For example, weak recommendations for the HPV vaccine are correlated with a lower 
likelihood of getting the HPV vaccine 31, 32. A national survey also revealed hesitancy to recommend the vaccine and 
inconsistent recommendations among providers33. Some studies have found that one-third to one-half of eligible 
patients do not receive any recommendation for the HPV vaccine from their provider 3, 32. Time constraints may also 
prevent providers from thoroughly discussing the HPV vaccine with their patients34, 35. 
The rising use of speech technology among consumers may open doors for patient-provider communication. Speech-
based dialogue systems are software agents that carry discourse with a user involving several speech turns. We propose 
the possibility of automated discourse that could mimic the dialogue interaction between the patient and provider and 
  
respond consistently to each patient. This could inspire the patient to initiate discussion about the HPV vaccine, while 
offsetting some of the communication responsibilities of the provider by preparing the patient to ask specific questions 
and discuss their decision in detail when they see their provider. Some studies have also noted that young adults want 
to discuss their vaccination decisions with providers36, 37, have misconceptions of the HPV vaccine and HPV38, and 
are at high risk for HPV infection39, 40. Also, the younger demographic may have different informational needs 
compared to adults, such as the emphasis of sexual health practices to prevent HPV transmission. As such, an 
automated dialogue system may help in tailoring the discourse for individual users. 
In a previous study41, we performed an initial usability trial on using a conversational agent for HPV vaccine 
counseling among parents with at least one child under 18. The trial was conducted using the Wizard of OZ protocol 
that simulates natural language interface tools for agents or robots with a human operator (“wizard”) in a remote area 
that is directing dialogue interaction of the machine42. The overall takeaway, despite some limitations on the speed of 
the “wizard” responses and the stoic speech, was receptiveness towards the ease of use and features of the agent, 
including interactivity of the dialogue and real-time question answering, useful information, and clarity of 
communication.  
In this study, we applied the same procedure on a sample of college-aged adults at a Texas public university. HPV 
vaccination rates in Texas are much lower than in the rest of the United States (32.9% - 26.6% for boys and 39.7% 
for girls)43. This time, we collected more detailed data, including perceived beliefs of the HPV vaccine and responses 
from validated usability surveys. One aspect we were interested in exploring was how an agent would fare with similar 
systems that employed a voice interface, which would provide feedback critical to evaluate the effectiveness of the 
design of our HPV conversational agent. Furthermore, we wanted to know the potential impact of a conversational 
agent on vaccine uptake, which is a cue to action that may be predicted by health beliefs44. If there is some early 
evidence that a conversational agent may have a positive impact on health beliefs, this may warrant further study. 
Therefore, we propose the following questions: 
• RQ1: What is the overall usability of a simulated conversational agent compared to the usability of most 
interactive voice user interfaces? 
• RQ2: Are there any correlations of the usability of the conversational agent with the various users’ perceived 
beliefs towards the HPV vaccine? 
• RQ3: Could a conversational agent for the HPV vaccine improve users’ perceived beliefs? 
Methods 
Participants were recruited from an undergraduate participant pool at Texas A&M University- College Station 
(TAMU) and chose to participate for an extra credit in a public speaking course1. Potential participants were young 
adults between the ages of 18 to 26. Out of 25 total participants, 11 were females and 14 were males, and the average 
age was 20 years. The majority were white (n=19) followed by Black (n=3), Hispanic (n=2) and Asian (n=1), 
respectively. 8 participants reported receiving the HPV vaccine, 8 reported not receiving the HPV vaccine, and 9 could 
not recall if they had received the vaccine. The study was conducted during the first week of April of 2019, utilizing 
the Wizard of OZ protocol42 where the dialogue exchange is handled by a drone operator of the conversational agent 
(designated as “Beverly”). During the study, 1 participant experienced technical difficulties and was removed from 
analysis, resulting in a final sample size of 24. 
Each participant was offered an explanation of the study (design, procedures, and risks) and was given time to ask 
questions; they were told that their participation was voluntary and that they could withdraw from the study at any 
time without negative consequence. If they agreed to participate, the study personnel obtained informed consent from 
them and the participant entered a designated observation area on the TAMU campus with a simulated conversational 
agent device (Wizard of OZ). The conversational agent, “Beverly,” initiated a conversation with the user and about 
HPV and the HPV vaccine for 20-30 minutes. The drone operator utilized a script designed by study personnel to 
counsel on the HPV vaccine41. After the simulated counseling information session, each participant completed surveys 
to evaluate usability of the conversational agent and assess their health beliefs regarding the HPV vaccine. 
 
1 The University of Texas Health Science Center’s Committee for the Protection of Human Subjects(HSC-SBMI-
19-0102),  and Texas A & M University Human Research Protection Program (IRB2019-0118M) approved this 
study. 
  
The surveys were modified from three instruments: the System Usability Survey (SUS)45, 46, the Speech User Interface 
Service Quality (SUISQ)47, 48, and the Carolina HPV Immunization Attitude and Belief Scale (CHIAS)49. SUS is a 
validated industry standard to provide a “quick and dirty” scoring for usability, with a rating between 0-100 derived 
from 10 survey items. The SUS score can be interpreted by associating it with a letter grade (i.e. 80-89 = B, 70-79 = 
C, etc.) or an adjective rating50, 51. 
SUISQ is a 25-question survey developed specifically for interactive voice response applications based on four factors: 
User Goal Orientation (8 items), Customer Service Behaviors (8 items), Speech Characteristics (5 items), and 
Verbosity (4 items). User Goal Orientation describes the “system’s efficiency, user trust, confidence in the system, 
and clarity of the speech interface.” Customer Service Behaviors involve “friendliness and politeness of the system, 
its speaking pace, and its use of familiar terms.” Speech Characteristics refer to “naturalness and enthusiasm of the 
system voice,” and Verbosity is the “talkativeness and repetitiveness of the system52.” Each item is on a Likert scale 
between 1 to 7 (1 for strongly disagree to 7 for strongly agree). The factor scores are the mean of all items in each 
category and an overall score is the mean of the factor scores (Verbosity mean is reversed).   
CHIAS is a 16-item survey with four factors (Perceived Barriers, Harms, Effectiveness, and Uncertainty) that are 
aligned with the health belief model44, a well-known health behavioral change model that has a long history in vaccine 
uptake research. Survey items for Perceived Barriers relate to "barriers to HPV vaccination including cost and access 
to a healthcare provider"49. Perceived Harms pertains to "perceived potential harms from the vaccine including health 
problems"49. Perceived Effectiveness and Uncertainty survey items describe subjective notions of the "effectiveness 
of HPV vaccine in protecting against genital warts and cervical cancer"49 and "not having enough information about 
the HPV vaccine and perception of community vaccination norms"49, respectively. Each survey item is on a Likert 
scale (1 for strongly disagree to 4 strongly agree).  Lower ratings represent positive attitudes towards the HPV vaccine. 
This survey has demonstrated stability of the factors to describe HPV vaccination attitudes over time. With the 
exception of the Perceived Effectiveness factor, the other three factors have been attributed to parent HPV vaccination 
intention and predicted HPV vaccination utilization of parents53. CHIAS is adaptable for young adults and has been 
shown to have similar validity to the parent version54, 55. This version targeted for young adults includes one additional 
factor called Risk Denial55, a factor relating to low perception of risk of the HPV infection. Two recent studies utilized 
this variation of CHIAS on samples of a young population under 25. Kamimura and colleagues utilized the Risk Denial 
and Benefit factors of the survey to measure differences between Vietnamese and United States college students56, 
while Hanson and associates focused on and measured the Perceived Effectiveness, Uncertainty, and Harms factors 
of the CHIAS model for their survey study57. 
We utilized the same software system that we developed to provide speech dialogue interaction with a natural language 
(NL) interface for the user41. The software was developed using iOS SDK for the tablet and Java for the desktop 
application to remotely interact with the user through the tablet’s NL speech interface. We also employed the same 
script in our previous trial, but we modified the language to reflect the target demographic. For example, a scripted 
statement like “[i]f your child is vaccinated with the HPV vaccine it will protect against various HPV viruses which 
causes many precancerous and cancerous lesions in males and females” became “if you are vaccinated with the HPV 
vaccine...” 
Results 
We collected survey responses from patients using the aforementioned instruments (SUS, SUISQ, and CHIAS). For 
four questions of the CHIAS survey, we reversed the scale to match the direction of the other CHIAS variables so that 
higher scores were indicative of lower receptiveness for the HPV vaccine. For the SUS survey, we omitted the question 
“I think I would like to use the system frequently,” because participants were unlikely to use the system again. 
According to Lewis & Sauro analyses, removal of this question would not have a major impact on the statistical 
validity of the SUS final score58. To compensate for the omitted question, we adjusted the SUS calculation58 because 
we do not foresee this agent being used every day as a consumer tool. Rather, we envisioned the agent to be situated 
in a clinical environment while the patient is waiting for their health care provider. Statistical analysis was completed 
through IBM SPSS v25.  
  
RQ1: For the primary question regarding 
overall usability, we computed a one sample t-
test against a reported average SUS score for 
voice interfaces, μ = 72 (n = 233)51. The 
analysis produced a t-statistic of t(23)=1.627, 
p=0.059. Overall, there is 94% confidence that 
the system has a score above the industry mean 
of 72. This would reveal that the conversational 
agent had an on-par or a slightly above average 
SUS score with industry-based interactive 
voice interface systems.  
We also looked at the differences between 
users by vaccination status (See Figure 1).  The 
SUS overall score was higher among those that 
never had the vaccine (μ = 80) compared to 
those that did have the HPV vaccine (μ = 77) 
and those did not know if they had the HPV 
vaccine (μ = 74). We also looked at the 
attributes of individuals in relation to the SUS score to ascertain any association with the SUS Score. A Fisher Exact 
Test (p = 0.54, 12.42) indicated a statistically marginally significant relationship between vaccination status and SUS 
score. None of the other attributes such as school classification, parents’ income, etc. indicated any significance with 
the SUS Score. 
While the SUS survey has a history of being a valid measurement tool for quick usability scoring, the SUISQ survey 
has yet to be as standardized as the SUS. We administered the SUISQ survey (See Table 1) in conjunction with SUS, 
as recommended by Lewis59. We looked at the correlation between SUS and SUISQ to ascertain any significant 
relationship. For the most part, there appears to be a positive correlation between SUS score and SUISQ score that is 
moderately strong and statically significant (r=0.486, p=0.016). For the User Goal Orientation and Verbosity factors 
of SUISQ, there also appears to be a strong, positive relationship with the SUS score (r=0.508, p=0.005 and r=0.627, 
p=0.000, respectively). There is also a moderately positive correlation between Customer Service Behavior score and 
SUS score (r=0.438, p=0.014). 
RQ2: To answer RQ2, we investigated any correlations 
for usability with the participants’ beliefs of the HPV 
vaccine. In comparing those who reported to not have 
received the HPV vaccine with those who reported to 
have received the HPV vaccine, we calculated the 
Spearman rank correlation. Among those that reported 
to not have received the HPV vaccine, there was a 
strong inverse relationship (i.e., a lower CHIAS rating 
indicates a greater propensity for the HPV vaccine) 
between SUISQ and the Perceived Effectiveness 
construct, which was statistically significant (rs= -.711, 
p=0.037). There was also a strong inverse relationship 
between the Verbosity factor of SUISQ and the 
Perceived Uncertainty construct for the CHIAS, which was statistically significant (rs= -0.874, p=0.05). Among those 
that reported to have received the HPV vaccine, there was a strong inverse relationship between the overall SUISQ 
score and the Perceived Barriers and Perceived Effectiveness constructs, which were statistically significant (rs= -
0.639, p=0.044 and rs= -0.655, p=0.039, respectively). In addition, there was a strong inverse relationship between 
the Verbosity factor of SUISQ and the Perceived Effectiveness construct, which was statistically significant (rs= -
0.764, p=0.014). 
RQ3: Lastly, we investigated if there was any improvement in the users’ perception of the HPV vaccine compared 
to samples from published studies conducted by Kamimura et al.56 and Hanson et al.57. We re-scaled our collected 
CHIAS data to match the scales for Kamimura’s and Hanson’s CHIAS data – a 5-point and 11-point scale, 
respectively. Then we computed a one-sample t-test with the means of the CHIAS factors using the CHIAS factors 
 
Figure 1. SUS Scores among different vaccination statuses. Red 
line is the average of all participants. Black line is the baseline 
mean measure reported for interactive voice interface systems.  
 
Table 1. SUISQ Factor means and overall score. 
SUISQ Factor Mean (SD), n=24 
User Goal Orientation 4.69 (0.96) 
Customer Service Behavior 6.09 (0.60) 
Speech Characteristics 3.10 (1.29) 
Verbosity (reversed) 3.26 (1.03) 
SUISQ Overall Score 4.29 (0.75) 
 
  
of the aforementioned studies. Table 2 summarizes our results where the green signifies statistical significance, gray 
signifies marginal statistical significance and red signifies no statistical significance. 
 
There appears to be better beliefs and perceptions with Risk Denial (μ =1.41, p=0.00), Perceived Harms (μ =1.92, 
p=0.00) and Perceived Uncertainty (μ =2.13, p=0.00) among the individuals who interacted with our conversational 
agent. There was some improvement if accounting for the marginally statistical significance with Perceived Barriers 
(μ =1.94, p=0.09). There was no evidence of improvement with Perceived Effectiveness despite a better rating (μ 
=3.82, p=0.26). 
Discussion 
This second attempt at the Wizard of OZ experiment was performed on young adults who are also potential targets 
for the HPV vaccine, considering the recently expanded approval of the vaccine for adults up to 45 years of age60. In 
this study, we administered a more detailed usability survey involving the System Usability Scale (SUS) and Speech 
User Interface Service Quality (SUISQ). SUS is a general usability measurement scale based on 10 Likert scaled 
questions that has proven reliability. While SUISQ is a more robust usability survey for voice user interfaces, it has 
yet to achieve the reliability of the SUS. Together they may provide further validation support for SUISQ59. We also 
administered a health belief model survey, the Carolina HPV Immunization Attitudes and Beliefs Scale (CHIAS), that 
was tailored for young adults55 to see if there were any correlations between the health belief constructs and usability 
variables. We compared the means for each of the constructs with those from previous studies that used this modified 
survey for a younger population56, 57. 
RQ1: The overall usability (i.e. satisfaction, effectiveness, and efficiency), measured through the SUS score, indicated 
the conversational agent had average to slightly better scores than many of the interactive voice interface systems (a 
SUS score of 77 versus 72; 94% confidence). Additionally, there was a marginally statistically significant relationship 
between SUS score and HPV vaccination status. There were slight variations of the SUS score among the different 
users in comparing those that had received the HPV vaccine (SUS score of 77) with those that did not know if they 
had received the vaccine (SUS score of 74). The individuals that never received the HPV vaccine rated the system 
high at 80. This score indicates that this tool could be effective for individual users who had never received the HPV 
vaccine and could perhaps inform and encourage them better than other paper-based methods. With a small sample 
size, we can conclude that there is preliminary evidence that our conversational agent (while simulated) has a strong 
usability for people who never received the HPV vaccine. In the future, we can further analyze why those that didn’t 
know if they received the HPV vaccine scored lower and perhaps look into methods to improve SUS scores among 
this group of individuals. 
RQ2: Lower values for the health belief ratings indicated a propensity for the HPV vaccine. Therefore, we sought any 
statistical significance showing an inverse relationship between the CHIAS constructs and usability factors. No 
significant relationship exists between SUS and the CHIAS constructs, but there are some statistically significant 
relationships between the SUISQ factors and the CHIAS constructs. Among the individuals who never received the 
HPV vaccine, there was a strong inverse relationship between SUISQ Overall Score and Perceived Effectiveness of 
the HPV vaccine. This would indicate that unvaccinated participants who liked the conversational agent are more 
likely to believe that the HPV vaccine is effective and consider getting vaccinated. Within that same group, the 
Table 2. Comparison of previous studies’ means of CHIAS constructs between agent and published studies. 
Lower values for CHIAS indicate positive attitudes in favor of the HPV vaccine. Green rows indicate statistical 
significance, gray rows represent marginally statistical significance, and red represents no statistical significance. 
Adjusted p-value calculated with Holm-Bonferroni using alpha level of .05. ±Kamimura, et, al.,+Hanson, et, al. 
CHIAS Construct Agent + CHIAS CHIAS p-value adjusted p-value 
Perceived Barriers 1.94 2.33 (n=437)± 0.09 .0125 
Risk Denial 1.41 2.00 (n=437)	 0.00 .01 
Perceived Harms 1.92 3.5 (n=108)+ 0.00 .01 
Perceived Effectiveness 3.82 4.3 (n=108)	 0.26 .02 
Perceived Uncertainty 2.13 4.8 (n=108)	 0.00 .01 
 
  
Verbosity factor — measuring how repetitive and talkative the agent is — had a significant inverse relationship with 
the Perceived Uncertainty construct. For background, the Verbosity score was reversed for analysis, so a high 
Verbosity score indicated low repetitiveness and talkativeness of the agent. Perceived Uncertainty represents 
sufficiency of information concerning the HPV vaccine. What we gather from our preliminary results for the 
relationship between Verbosity and Perceived Uncertainty is that the content and information related to the vaccine 
and HPV-related diseases that was spoken by the system was not deemed meaningless and was adequate for the user. 
Of interest, the individuals who reported to have received the HPV vaccine also shared the same relationship pairing 
— Verbosity ≈ Perceived Uncertainty, and Overall SUISQ ≈ Perceived Effectiveness. Also, SUISQ had a significant 
relationship with the Perceived Uncertainty and Perceived Barriers constructs. The Perceived Barriers rating reveals 
any external challenges that could impede obtaining the HPV vaccine. Since individuals reported having the HPV 
vaccine, it is clear they overcame any barriers that could have prevented them from obtaining the HPV vaccine. The 
various relationships with several variables are more likely due to them already having the HPV vaccine, since the 
SUISQ overall score was associated with three of the five CHIAS constructs. 
RQ3: When we analyzed the Carolina HPV Immunization Attitudes and Beliefs Scale (CHIAS) user data with the 
CHIAS mean results from other published studies that used the same survey56, 57, there was a statistical difference (i.e., 
improvement) with various means of the constructs from the CHIAS. Aside from the Perceived Effectiveness 
construct, there was also a marginally significant statistical difference with the Perceived Barriers construct. In absence 
of a true control group, there is some evidence of impact on health beliefs and perceptions of the HPV vaccine as a 
result of using a conversational agent for the HPV vaccine. 
Limitations: This study has several important limitations. The most significant limitation is that the study lacked a 
control group. Because we needed to have as many participants as possible to provide stronger analysis of the results, 
we had all of the participants interact with the conversational agent and used the means data for some of the constructs 
to compare with existing studies. Also, with the lack of resources and time (and the nature of human computer-
interaction studies), the sample size was relatively small and is not generalizable to a larger population. With a larger 
sample size, some of the marginally significant statistical findings could have had more validity. Among those that 
reported not knowing whether they received the HPV vaccine, no significant inverse relationship with any of the 
variables existed, so we need to investigate why this was the case. It might be possible that they have low health 
literacy, but we cannot be certain unless we measure their health literacy skills. It may also be due to their lack of 
interest in their personal health, in which case a tailored dialogue intervention may be needed for this group. Another 
limitation is that the age group recruited through this study (young adults) may differs from another intended 
demographic who will use our conversational agent, namely parents of pediatric patients. Although parents were 
receptive to the usability of the conversational agent in a previous study41, we have not yet gathered data on their 
beliefs towards the HPV vaccine, which may not necessarily be the same as those of college-aged adults. 
Conclusion 
Overall, based on the initial analysis, we conclude that our initial design for a conversational agent for the HPV vaccine 
is robust and likely to be consistent with industry standards. Future assessments with a larger, more diverse population 
would allow us to further validate the usability and likeability of our conversational agent. Also, the usability may 
have some correlation with the health beliefs of its users as it relates to the HPV vaccine. Lastly, based on comparisons 
with previous studies assessing health beliefs among young adults, the conversational agent could potentially impact 
the health beliefs of the users as it pertains to the HPV vaccine. This study provides initial evidence on the validity of 
using a conversational agent to improve vaccination rates. While these results are preliminary at best and lack a large 
sample size, there is some promise that deploying this type of tool within a health care environment could be feasible, 
especially since conversational agents promote patient-centered communication, which is important to achieve better 
health outcomes. Also, the relatively good usability rating which encompasses overall satisfaction could be analogous 
to patient satisfaction, which is an important outcome of patient-centered communication that we discussed earlier. In 
addition, the implementation of conversational agents in a health setting could possibly address some of the 
communication challenges rooted in demographic disparities (language barriers, low health literacy, etc.), and offload 
some of the communication burdens that impede on providers’ time. However, additional research is needed to further 
validate our findings. This work could potentially be extended to other vaccine needs and health topics as well. 
Future Direction: In this study and the last, we utilized the Wizard of OZ protocol to simulate a conversational agent 
for the HPV vaccine as a pilot study. Our next endeavor is to provide a fully automated agent to provide discourse on 
the HPV vaccine with health consumers. Currently, we have developed some of the knowledge bases61-64 and software 
components that can provide this interaction65, 66, and we plan on live testing them sometime in the near future with 
  
both parents and young adults. Overall, this experience with the simulated system provided us with knowledge for 
future development and planning for an autonomous conversational agent that can counsel patients on receiving the 
HPV vaccine, with the potential to be extended towards other health promotion topics. 
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